GlassScriptPhysician profile
Rebekah S Mcclain
NPI 1992266696
$2,317.54
in general payments reported to CMS, 2019-2025
24 companies · $843 in 2025
The $843 reported for 2025 was more than what 90% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.73 · 2023: $427 · 2024: $1,026 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $313.84 | 2023-2025 | Veozah |
| Abbvie INC. | $284.36 | 2023-2025 | |
| Biogen, INC. | $251.37 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $212.69 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $179.02 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $165.59 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $159.95 | 2024 | |
| Minerva Surgical, INC | $110.66 | 2024 | |
| Avanos Medical | $103.39 | 2024 | On-Q* Pump and Accessories |
| Shield Therapeutics INC | $100.01 | 2024-2025 | |
| Exeltis, USA INC. | $78.58 | 2023-2025 | Slynd |
| Millicent US INC | $59.72 | 2024-2025 | Intrarosa |
| Merck Sharp & Dohme LLC | $39.87 | 2024-2025 | Gardasil 9, Gardasil |
| Pfizer INC. | $38.21 | 2024 | |
| Agile Therapeutics, INC. | $36.44 | 2023-2024 | Twirla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.72 | 2025 | Novasure, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exact Sciences Corporation | $28.96 | 2024 | Cologuard Collection Kit |
| Morphosys, US INC. | $21.73 | 2022 | |
| Aspira Women'S Health INC | $20.26 | 2024 | Ova1 |
| Smith+Nephew, INC. | $19.17 | 2025 | Pico 7 |
| Pacira Pharmaceuticals Incorporated | $17.22 | 2023 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2024 | |
| Meditrina | $15.27 | 2025 | |
| Organon LLC | $11.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.